|Description||Burosumab is a human monoclonal antibody targeting the phosphaturic hormone fibroblast growth factor 23 (FGF23). Burosumab is currently in a phase III clinical trial for the treatment of patients with X-linked hypophosphatemia.|
|Brife Description||human monoclonal antibody|
|Synonyms||KRN-23; KRN 23; KRN23|
|Application||the potential treatment of X-linked hypophosphatemia|
|Current Developer||Ultragenyx Pharmaceutical; Kyowa Hakko Kirin|
Moguisteine is a novel peripheral nonnarcotic antitussive agent that has proved to be as active as codeine in several experimental models of induced cough in gu...
Labetalol is a competitive antagonist of both α- and β-adrenoreceptors that is used to treat high blood pressure.
Pipobroman (trade names Vercite, Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. It is marketed by Abbott Laboratories. Pipobroman (P...
sulfo-SPDB-DM4 is adrug-linker conjugate for ADC and DM4 with a reactive linker sulfo-SPDB, which can react with antibody to make antibody drug conjugate.
Atrial natriuretic factor (1-28) (human,
Atrial natriuretic factor (1-28) (human, porcine) is a 28 amino acid peptide corresponding to the rat protein sequence. It is an endogenous peptide synthesized ...
Benazepril, an angiotensin converting enzyme inhibitor, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic ...
20(S)-Hydroxycholesterol is an allosteric activator of the Hedgehog signaling pathway Smoothened (Smo) oncoprotein. 20(S)-Hydroxycholesterol induces Smo accumul...
Ponatinib hydrochloride is an oral drug for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leuke...